Prodrugs are molecules with little or no pharmacological activity that are converted to the
active parent drug in vivo by enzymatic or chemical reactions or by a combination of the two …

Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the
treatment of cancer. For more than two decades, the IRT prodrug has largely contributed to …

The carbamate group is a key structural motif in many approved drugs and prodrugs. There
is an increasing use of carbamates in medicinal chemistry and many derivatives are …

Mammalian carboxylesterases (CEs) are key enzymes from the serine hydrolase
superfamily. In the human body, two predominant carboxylesterases (CES1 and CES2) …

Mammalian carboxylesterases hydrolyze a wide range of xenobiotic and endogenous
compounds, including lipid esters. Physiological functions of carboxylesterases in lipid …

Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or
chemical transformation in vivo to release the active parent drug, which can then exert the …

Carboxylesterases are a multigene family of mammalian enzymes widely distributed
throughout the body that catalyze the hydrolysis of esters, amides, thioesters, and …

Irinotecan is a topoisomerase inhibitor, widely used in treatment of malignancies including
pancreatic ductal adenocarcinoma (PDAC) as part of the FOLFIRINOX regimen prescribed …

This review covers current developments in molecular-based studies of the structure and
function of carboxylesterases. To allay the confusion of the classic classification of …

Mammalian carboxylesterases (CESs) comprise a multigene family whose gene products
play important roles in biotransformation of ester-or amide-type prodrugs. They are members …